ProPhase Labs Management
Management criteria checks 2/4
ProPhase Labs' CEO is Ted Karkus, appointed in Jun 2009, has a tenure of 14.92 years. total yearly compensation is $902.20K, comprised of 74.8% salary and 25.2% bonuses, including company stock and options. directly owns 19.86% of the company’s shares, worth $16.52M. The average tenure of the management team and the board of directors is 0.8 years and 11.9 years respectively.
Key information
Ted Karkus
Chief executive officer
US$902.2k
Total compensation
| CEO salary percentage | 74.8% |
| CEO tenure | 14.9yrs |
| CEO ownership | 19.9% |
| Management average tenure | less than a year |
| Board average tenure | 11.9yrs |
Recent management updates
Recent updates
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04
ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12ProPhase Labs opens Covid testing facility in New York
Jan 29ProPhase Labs announces $5.5M registered direct offering of common stock and warrants
Jan 05ProPhase Labs expands COVID-19 testing capacity in New York, shares +21%
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | US$7m |
| Dec 31 2022 | US$902k | US$675k | US$18m |
| Sep 30 2022 | n/a | n/a | US$31m |
| Jun 30 2022 | n/a | n/a | US$27m |
| Mar 31 2022 | n/a | n/a | US$18m |
| Dec 31 2021 | US$941k | US$590k | US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$2m |
| Mar 31 2021 | n/a | n/a | -US$460k |
| Dec 31 2020 | US$445k | US$125k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$2m |
| Jun 30 2020 | n/a | n/a | -US$2m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$249k | US$125k | -US$3m |
| Sep 30 2019 | n/a | n/a | -US$3m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$3m |
| Dec 31 2018 | US$2m | US$210k | -US$2m |
| Sep 30 2018 | n/a | n/a | -US$1m |
| Jun 30 2018 | n/a | n/a | -US$826k |
| Mar 31 2018 | n/a | n/a | -US$1m |
| Dec 31 2017 | US$2m | US$675k | -US$2m |
Compensation vs Market: Ted's total compensation ($USD902.20K) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.
CEO
Ted Karkus (64 yo)
14.9yrs
Tenure
US$902,200
Compensation
Mr. Ted William Karkus has served as the Chief Executive Officer of ProPhase Labs, Inc. since June 2009. Mr. Karkus founded 2001 Forrester Financial LLC and served as its Managing Member. He is a Managemen...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 14.9yrs | US$902.20k | 19.86% $ 16.5m | |
| Chief Operating Officer & Head of Finance Department | less than a year | no data | no data | |
| Controller | 1.3yrs | no data | no data | |
| Executive VP & Chief Information Officer | less than a year | no data | no data | |
| President of Nebula Genomics | less than a year | no data | no data | |
| Senior VP and Director of Sales & Marketing - Nebula Genomics | 1.3yrs | no data | no data |
0.8yrs
Average Tenure
49yo
Average Age
Experienced Management: PRPH's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 14.9yrs | US$902.20k | 19.86% $ 16.5m | |
| Independent Director | 14.9yrs | US$322.30k | 1.52% $ 1.3m | |
| Independent Director | 8.9yrs | US$322.30k | 0.17% $ 142.7k | |
| Independent Director | 5yrs | US$337.30k | 0% $ 0 |
11.9yrs
Average Tenure
64.5yo
Average Age
Experienced Board: PRPH's board of directors are seasoned and experienced ( 11.9 years average tenure).